Article Details

Exscientia starts trials of first AI-derived cancer immunotherapy

Retrieved on: 2021-04-12 09:42:43

Tags for this article:

Click the tags to see associated articles and topics

Exscientia starts trials of first AI-derived cancer immunotherapy. View article details on hiswai:

Excerpt

Exscientia was the first company to start human trials of a new drug designed using artificial intelligence (AI) last year, and now says it has started ...

Article found on: pharmaphorum.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up